Big Pharma Finds New Pipeline Source: Each Other
Executive Summary
As Big Pharma's pipeline crunch continues, so does competition for late-stage licensing opportunities, driving up late-stage deal values. A notable trend behind these rising values is a spate of Big Pharma cross-licensing deals.
You may also be interested in...
Top Biotech Licensings of 2004
Judging by the top ten biotech alliances of 2004, biotech's late-stage pipelines have largely been picked clean by Big Pharma licensees. The trend toward earlier stage deals among the top ten alliances in 2003 we noted last year has become even more prominent.
Top Biotech Licensings of 2004
Judging by the top ten biotech alliances of 2004, biotech's late-stage pipelines have largely been picked clean by Big Pharma licensees. The trend toward earlier stage deals among the top ten alliances in 2003 we noted last year has become even more prominent.
In Pursuit of Primary Care, Schering-Plough Is Growing against the Grain
The marketing deal between Schering-Plough and Bayer gives Schering additional products it can sell along with its recently approved cholesterol drug Vytorin, and a significant number of reps to help it do so. As such, the deal reinforces Schering's commitment to building a primary care franchise. But it also runs counter to an emerging trend among many Big Pharmas to focus increasingly on higher-value specialist markets, which do not require a huge sales and marketing infrastructure--or the regular flow of new primary-care products necessary to support it.